Chun Lin, MD
Interventional Cardiology · San Francisco, CANPI 1356532261
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 37.6% of the total.
Across 212 payments — averaging $344.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$27K
- Abbott$25K
- Edwards Lifesciences$6K
- Medtronic$5K
- Penumbra, Inc.$5K
- Abiomed$4K
- plus $580 from 14 others
Across 30 payments — averaging $31,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$479K
- Siemens Medical Solutions USA, Inc.$458K
What the payments were for
- Consulting fees$36,96351%
- Speaking & faculty fees$20,01427%
- Travel & lodging$8,40812%
- Food & beverage$7,66610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 38 | $27,476 |
| Abbott | 43 | $24,940 |
| Edwards Lifesciences | 47 | $6,489 |
| Medtronic(2 entities) | 52 | $5,353 |
| Penumbra, Inc. | 5 | $4,556 |
| Abiomed | 7 | $3,657 |
| Siemens Medical Solutions USA, Inc. | 3 | $170 |
| Impulse Dynamics (USA) Inc. | 2 | $73 |
| Baxter Healthcare | 2 | $60 |
| Cardiac Dimensions, Inc. | 1 | $40 |
| Merit Medical Systems Inc | 1 | $36 |
| B. Braun Interventional Systems Inc. | 1 | $30 |
| Amgen | 2 | $28 |
| Tactile Systems Technology Inc | 2 | $27 |
| Pfizer | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Johnson & Johnson | 1 | $17 |
| Grifols USA, LLC | 1 | $12 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE CARDIOFORM ASD Occluder$14,498
- GORE CARDIOFORM Septal Occluder$13,780
- AMPLATZER Occluders$11,192
- CARDIOFORM Septal Occluder$11,000
- AMPLATZER TALISMAN$8,563
- RUBY Coil$4,462
- AMPLATZER AMULET$4,000
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,970
- Impella$3,607
- HARMONY$2,530
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$1,251
- Melody$965
- AMPLATZER PICCOLO$134
How this compares
$73,051 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $20,438 |
| XareltoRivaroxaban | 11 | $16,501 |
| BrilintaTicagrelor | 16 | $7,647 |
| Enoxaparin Sodium | 15 | $720 |
| ClopidogrelClopidogrel Bisulfate | 59 | $674 |
| Metoprolol Succinate | 59 | $444 |
| Rosuvastatin Calcium | 36 | $390 |
| Atorvastatin Calcium | 52 | $366 |
| Losartan Potassium | 19 | $300 |
| Potassium Chloride | 18 | $297 |
| Warfarin Sodium | 12 | $201 |
| Hydrochlorothiazide | 18 | $97 |
| Amlodipine Besylate | 18 | $88 |
| Atenolol | 14 | $23 |
| Lisinopril | 19 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $20,43817 claims |
| Johnson & JohnsonXarelto | $17 | $16,50111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in San Francisco
- Yousif AhmadSan Francisco$205K
- Bao TranSan Francisco$130K
- Sammy ElmariahSan Francisco$126K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.